USL311 / Sawai Pharma, Ligand - LARVOL DELTA

Fumarate-associated immunometabolic network in Periodontitis revealed by integrated transcriptomic and single-cell RNA sequencing analysis. (PubMed, PLoS One) - "In addition, computational drug screening and molecular docking highlighted carbenoxolone and a CXCR4 antagonist (USL311) as potential candidates for future study. Overall, this study provides an integrative view of fumarate-associated immunometabolic alterations in periodontitis and identifies candidate transcriptomic markers and therapeutic hypotheses that warrant further experimental validation."

Journal • Dental Disorders • Inflammation • Periodontitis • MEF2C

Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - P1/2; N=26; Terminated; Sponsor: Proximagen, LLC; N=120 ➔ 26; Recruiting ➔ Terminated; Trial primary completion date: Sep 2022 ➔ Jul 2020; Business reasons not related to safety

Clinical • Combination therapy • Enrollment change • Trial primary completion date • Trial termination • Brain Cancer • Glioblastoma • Oncology • Prostate Cancer • Solid Tumor

Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - P1/2; N=120; Recruiting; Sponsor: Proximagen, LLC; Active, not recruiting ➔ Recruiting; Trial primary completion date: Dec 2019 ➔ Sep 2022

Clinical • Combination therapy • Enrollment open • Trial primary completion date